You are here: Home » News-IANS » Health-Medicine
Business Standard

Capping stent prices to affect patients, slab pricing right way: Ramadoss

IANS  |  Chennai 

The central government's move to cap the stent prices may backfire and affect Indian patients and also the medical tourism potential, former Union Health Minister Anbumani Ramadoss said on Friday.

He also said making doctors prescribe drugs by their generic names was a good move but the issue of drug quality check had to be strengthened.

Ramadoss, a qualified medical doctor, told IANS that "capping the prices of stents may make manufacturers exit the Indian market which in turn would affect the patients".

According to him, Indian patients would be affected to a large extent and so would be in-bound medical tourism (foreign patients coming to India for surgeries/treatment) into India.

"The government should have stipulated prices on slab basis. There should be two or three slabs on pricing of stents," Ramadoss said.

The National Pharmaceutical Pricing Authority capped the prices of drug eluting stents (DES) and bioresorbable stents at Rs 29,600, and that of bare metal stents at Rs 7,260 in February-excluding local taxes.

The medical devices industry had suggested to the government that the stent's average price to the hospital should be the basis for arriving at the price band.

Ramadoss, a Lok Sabha member of the PMK from Tamil Nadu's Dharmapuri, agreed with the industry's fear that companies may reduce their research and development (R&D) spend and exit the Indian market if the revised prices do not cover even the cost.

Terming the Centre's move to make doctors prescribe drugs by their generic name and not by their brand name as "good", Ramadoss said quality checks of drugs made in India have to beefed up.

"The drug quality is a state subject in India. In India checking drug quality is an issue," he said.

According to him, the chemist will now try to push products of those manufacturers who give him higher margins.

In a recent report, investment banking firm Jefferies had said: "In our view, without steps for improving quality standards for drugs available in the market, the move will not have much material impact and will shift power from doctors to pharmacists."

According to Jefferies, transition to generics is a long term aim where the first step needs to be quality.



(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, April 28 2017. 18:54 IST